ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/CD19
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/CD19
18
trial(s) found.
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Leukaemia
Mantle cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06528301
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies (
UB-VV111-01
)
gene therapy,CAR-T-cell generating,CD19-targeting
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06526793
Haem
Phase 2
Recruiting
A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (
SOUNDTRACK-B
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
Non-Hodgkin's lymphoma
NSW
2109 - North Ryde - Macquarie University Hospital
2217 - Kogarah - St George Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06486051
Haem
Phase 2
Recruiting
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (
ENABLE-2
)
CAR-T-cell therapy
CAR-T-cell therapy,CD19-targeting
Cyclophosphamide
Fludarabine
WZTL002
alkylating agent
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
cell therapy
cytotoxic chemotherapy
+ CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06256484
Haem
Phase 1
Recruiting
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (
ATA3219-NHL-103
)
allogeneic CAR-T-cell therapy,CD19-targeting
Non-Hodgkin's lymphoma
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06137118
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06079164
Haem
Phase 1
Recruiting
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma (
KT-US-656-0601
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05643742
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies (
CRSP-ONC-006
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05605899
Haem
Phase 3
Recruiting
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (
ZUMA-23
)
autologous CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT05512390
Haem
Phase 1
Recruiting
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies (
M22-716
)
anti-CD19 antibody-drug conjugate,glucocorticoid receptor modulator
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - One Clinical Research
NCT05421663
Haem
Phase 1
Recruiting
A Phase 1b Multicenter, Open-Label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-Cell Non-Hodgkin Lymphoma (
90014496LYM1001
)
autologous CAR-T cell therapy,bispecific CD19/CD20-targeting
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05365659
Haem
Phase 1
Recruiting
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas (NHL) (
IKS03-01
)
anti-CD19 antibody-drug conjugate
B-cell lymphoma
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05327894
Haem
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year with KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT04994717
Haem
Phase 3
Recruiting
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT04637763
Haem
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (
CB10A
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell lymphoma
Lymphoma
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3121 - Richmond - Epworth Freemasons Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04594642
Haem
Phase 1
Recruiting
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (
D7400C00006
)
bispecific T-cell engager,CD19-targeting
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT03601442
Haem
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital (AVAILABLE)
ACTRN12621000762853
Haem
Phase 1
Recruiting
Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy
autologous CAR-T-cell therapy,CD19-targeting
B-cell malignancy
Leukaemia
Non-Hodgkin's lymphoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Recruitment Country and State
VIC (13)
WA (10)
NSW (10)
QLD (6)
SA (4)
NZ (1)
ACT (1)
TAS (1)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (3)
Phase 2 (2)
Phase 3 (3)
Trial Type
Haem (18)
Cancer Therapy Class
CD19
100%
CD20
17%
BTK
6%
mTOR
6%
mTORC1
6%
mTORC2
6%
Facility
3004 - Melbourne, Southbank - Alfred Health (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (4)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2217 - Kogarah - St George Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
6009 - Nedlands - Linear Clinical Research (1)
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
3168 - Clayton - Monash Children's Hospital (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
6009 - Perth - Perth Children's Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2605 - Garran - The Canberra Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
B-cell lymphoma
Mature B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Leukaemia
Lymphoid leukaemia
Follicular lymphoma
Chronic lymphocytic leukaemia
Acute lymphoblastic leukaemia
Mantle cell lymphoma
B-cell acute lymphoblastic leukaemia/lymphoma
Marginal zone lymphoma
Small Lymphocytic Lymphoma
Mixed phenotype acute leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy